Moody’s improves outlook for Bristol-Myers Squibb following FDA approval for Onglyza

Moody’s lifts Bristol-Myers outlook to ‘Stable’

NEW YORK — Moody’s Investors Service raised its outlook on drugmaker Bristol-Myers Squibb Co. to “Stable” from “Negative” Monday after regulators approved Bristol-Myers’ diabetes treatment Onglyza.

Full article »

FDA clears potential blockbuster diabetes drug from drugmakers Bristol-Myers and AstraZeneca

FDA approves new diabetes drug Onglyza

WASHINGTON — Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC.

Full article »

Product Recalls: Quick-set infusion sets used with insulin pumps

Recalls: infusion sets for diabetes patients

The following recall has been announced:

Full article »

Type I diabetes can be restrict by controlling immune system

diabetes-type-ITests under way to see if controlling immune system might curb Type 1 diabetes

Full article »

FDA advisers to vote on potential approval of 3 more anti-psychotic drugs for youngsters

FDA panel to vote on psychiatric drugs for kids

WASHINGTON — Advisers to the Food and Drug Administration are scheduled to vote Wednesday on whether three powerful psychiatric drugs should be approved for children, despite side effects that can increase the risk of diabetes.

Full article »

Product recalls: insulin pumps, girls’ raincoats

Recalls: insulin pumps, girls’ raincoats

The following recalls have been announced:

Full article »

Product recalls: insulin pumps


The following recalls have been announced:

— Disetronic Medical Systems Inc. is recalling select ACCU-CHEK Spirit insulin pumps, because of a potential defect in the up and down buttons. The buttons may intermittently or completely stop functioning and may fail to respond to button pressing with a vibration or acoustic signal. The recalled pumps have serial numbers ranging from SN02119552 through SN10006093. Details: by phone at 800-778-5095.

Protected by Comment Guard Pro